Directives Nationales de Prise en Charge de l’Hypertension Artérielle

Objectives

Strengthen prevention, early detection, integrated treatment and complication management for hypertension in Côte d’Ivoire, treating it as a priority non-communicable disease within national health planning and the integrated 2015–2019 non-communicable disease strategy.[1]The guidance responds to a substantial cardiovascular burden, with hypertension reported in 40% of adults aged 25 years and over in 2018, and seeks to reduce premature mortality, disability, household economic hardship, productivity losses and social inequalities associated with chronic disease.[2][3]

• Improve the quality, effectiveness and efficiency of hypertension care, patients’ quality of life, and adherence to national standards and good practice.[1]
• Increase detection of hypertension, assess cardiovascular risk and secondary causes, identify target-organ damage, treat patients, and manage complications and hypertensive emergencies.[4][5]
• Normalise blood pressure and prevent long-term complications, generally aiming for blood pressure below 140/90 mmHg within the first six months, subject to specified adjustments for people aged 80 years and over.[6][7]
• Prioritise prevention through screening, physical activity, tobacco cessation, avoidance of excessive alcohol consumption, healthier diets, salt reduction and improved adherence to prescribed treatment.[8][9][10]
• Strengthen primary healthcare delivery through the national minimum package of activities and adaptation of the World Health Organization essential package of non-communicable disease interventions to the Ivorian context.[3][4]
• Reduce pressure on specialised services by decentralising chronic disease management and bringing prevention and care closer to communities.[4][10]

Implementation

Implement hypertension care throughout the health-system pyramid, centred on primary healthcare and supported by referral to secondary and specialist services for uncontrolled, resistant, complicated or suspected secondary hypertension.[1][11][6]Care combines structured clinical assessment, lifestyle and dietary support, medicines where indicated, scheduled follow-up, emergency referral, and patient-centred education and shared decision-making.[11][6][12]

• Develop and validate national guidance through a multidisciplinary process involving general practitioners, pharmacists, diabetologists, midwives, specialised educators, administrative staff, clinical and scientific experts, and a wide range of health authorities, training institutions and technical partners, including the World Health Organization.[13][14]
• Review national and international guidance, including the minimum activity package and World Health Organization recommendations, and adapt interventions to local technology and medicine availability.[14][15]
• Translate directives into simple hypertension-care algorithms and train district health personnel in protocol use through workshops, presentations, group work and plenary validation.[15]
• Screen people aged over 40 years, people of any age with a family history of early hypertension, and people with diabetes, sleep apnoea or kidney disease; measure blood pressure in every patient attending a consultation.[16][8]
• Standardise screening by ensuring five minutes’ rest, correct positioning and cuff selection, an internationally recommended device, two readings separated by two to three minutes, recording of results, and communication of the result to the patient.[8]
• Confirm hypertension through repeated consultation-based measurement, normally using at least two measurements per consultation across two to three consultations, while allowing immediate clinical decisions for severe blood pressure elevation at or above 180/110 mmHg.[5]
• Assess patients through history-taking, examination and complementary tests for cardiovascular risk, secondary hypertension and damage to the brain, eyes, heart, kidneys and peripheral vessels.[5][17]Primary-level teams include general practitioners, nurses, midwives, healthcare assistants and community health workers, while secondary services add clinicians with relevant expertise, laboratory technicians and social workers.[17][11]
• Provide essential equipment and guidance at primary level, including blood-pressure monitors, weighing and height measures, tape measures, urine-testing strips and national management guidelines; provide electrocardiography and laboratory capacity at secondary level.[11]
• Deliver lifestyle counselling to all patients, promoting regular physical activity, weight reduction where appropriate, reduced salt and alcohol consumption, smoking cessation, diets rich in fruit and vegetables and low in saturated fat, and healthier fat choices.[6][9][10]Smoking-cessation support may include referral to designated cessation services.[9]
• Conduct an initial information and disclosure consultation covering risks, treatment benefits, objectives and the care plan, and use shared clinician-patient decision-making to support adherence.[12]Explain long-term medicine use, verify understanding, encourage an adequate medicine supply, and reinforce continuation after symptoms resolve.[10]
• Use antihypertensive medicines when indicated, beginning with evidence-supported drug classes and escalating to fixed-dose combinations or triple therapy where needed.[6][18][19]The guidance lists beta-blockers, diuretics, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, angiotensin II receptor antagonists, centrally acting antihypertensives and fixed-dose combinations.[18][19][20]
• Schedule follow-up at months 0, 1, 2, 3, 6, 9 and 12 and annually thereafter, with monthly consultations during the first six months until control is achieved.[11][12]Assess blood pressure, weight, treatment tolerance, adherence, biochemical findings, education needs and dietary advice, and encourage home blood-pressure measurement.[11][6]
• Manage hypertensive emergencies according to acute visceral complications rather than blood-pressure values alone, establish venous access, hospitalise and urgently refer where vital organs are affected, and monitor parenteral treatment every 15 minutes in the first hour, every 30 minutes in the second hour and hourly thereafter.[21][16]

Monitoring & Evaluation

Monitoring is principally embedded in clinical assessment, follow-up, emergency safety procedures and guideline validation rather than in a national results framework. The guidance does not define routine performance indicators, aggregate reporting requirements, surveillance arrangements, audit procedures or a formal accountability framework for hypertension implementation.[22][14][15][4][11][6]

• Confirm hypertension through repeated consultation-based blood-pressure measurement, normally taking at least two measurements per consultation over two to three consultations; permit immediate decisions in severe cases at or above 180/110 mmHg.[4][5]
• Record first and second screening blood-pressure readings in a screening form or health record, following a standardised procedure that includes rest, correct positioning, appropriate cuff selection and two readings separated by two to three minutes.[8]
• Assess cardiovascular risk, target-organ damage and possible secondary hypertension through clinical examination and complementary investigations, including renal function, blood glucose, lipids, urine testing and electrocardiography where available.[4][5][17]
• Review patients at scheduled intervals during the first year, including months 0, 1, 2, 3, 6, 9 and 12, followed by annual reviews; assess history, weight, blood pressure, biochemistry, education, diet, treatment tolerance and adherence.[11][6]
• Use monthly medical consultations during the first six months until blood-pressure control is achieved, reinforcing education while assessing treatment effectiveness and tolerance.[12]
• Use achievement of blood-pressure control within six months, with a general target below 140/90 mmHg subject to specified adjustments for people aged 80 years and over, as a clinical treatment objective.[6]
• Refer patients whose hypertension remains uncontrolled after six months of triple therapy, and refer resistant, complicated or suspected secondary hypertension for specialist assessment.[6]
• Monitor hypertensive emergencies according to acute organ complications rather than blood-pressure values alone, hospitalising patients at risk, investigating destabilising factors and reassessing patients over the medium term.[21][16]
• Undertake close surveillance for sublingual emergency treatment and monitor patients receiving parenteral treatment every 15 minutes during the first hour, every 30 minutes during the second hour and hourly thereafter.[16]
• Validate guideline content through multidisciplinary review, technical workshop discussions, group work, plenary feedback and expert scrutiny; update the directives in 2020 unless major research developments require earlier revision.[14][15]

Costing & Financing

No explicit implementation budget, medicine price list, financing allocation, funding source, resource-mobilisation plan, quantified funding gap or economic assumption is provided. The material nevertheless identifies affordability pressures from chronic disease care and specifies service inputs that have resource implications.[22][13][2][3][11][16]

• Recognise that chronic disease treatment is described as very costly and inaccessible to a large share of the population, while specialised services face substantial pressure.[2]
• Recognise that the costs of chronic disease care may raise household expenditure, contribute to job losses and worsen poverty and social inequalities.[3][4]
• Promote prevention and management approaches intended to increase the proportion of patients receiving optimal care with good cost-effectiveness.[3]
• Provide primary-care inputs including national management guidance, blood-pressure monitors, weighing scales, height measures, tape measures and urine-testing strips, alongside staff such as general practitioners, nurses, midwives, healthcare assistants and community health workers.[17][11]
• Provide secondary-care capacity including clinicians competent in hypertension and related specialties, laboratory technicians, social workers, electrocardiography and laboratory testing for glucose, lipids, urea, creatinine, proteinuria, electrolytes and full blood counts.[11]
• Support emergency-care capacity through peripheral venous access, emergency medicines including captopril, nicardipine and intravenous furosemide, and oxygen where available; no costs are attached to these inputs.[21][16]
• Account for the availability of technologies and medicines when adapting international recommendations and national guidance to the Ivorian context.[14]
• Note that the source identifies named facilities providing diabetes and hypertension clinics, but does not specify their budgets, financing arrangements or operating costs.[20][23]